Across the recent three months, 14 analysts have shared their insights on Axsome Therapeutics (NASDAQ:AXSM), expressing a variety of opinions spanning from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 7 | 6 | 1 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 3 | 2 | 1 | 0 | 0 |
| 2M Ago | 0 | 0 | 0 | 0 | 0 |
| 3M Ago | 3 | 4 | 0 | 0 | 0 |
The 12-month price targets, analyzed by analysts, offer insights with an average target of $199.57, a high estimate of $260.00, and a low estimate of $154.00. Witnessing a positive shift, the current average has risen by 12.52% from the previous average price target of $177.36.
Analyzing Analyst Ratings: A Detailed Breakdown
A comprehensive examination of how financial experts perceive Axsome Therapeutics is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Raghuram Selvaraju | HC Wainwright & Co. | Raises | Buy | $260.00 | $200.00 |
| David Amsellem | Piper Sandler | Raises | Overweight | $223.00 | $148.00 |
| Benjamin Burnett | Wells Fargo | Raises | Overweight | $193.00 | $157.00 |
| Sean Laaman | Morgan Stanley | Raises | Equal-Weight | $204.00 | $196.00 |
| Ashwani Verma | UBS | Raises | Buy | $248.00 | $163.00 |
| Raghuram Selvaraju | HC Wainwright & Co. | Raises | Buy | $200.00 | $185.00 |
| Ami Fadia | Needham | Raises | Buy | $169.00 | $154.00 |
| Graig Suvannavejh | Mizuho | Raises | Outperform | $202.00 | $200.00 |
| Sean Laaman | Morgan Stanley | Raises | Overweight | $196.00 | $194.00 |
| Raghuram Selvaraju | HC Wainwright & Co. | Raises | Buy | $185.00 | $180.00 |
| Leonid Timashev | RBC Capital | Raises | Outperform | $198.00 | $189.00 |
| Benjamin Burnett | Wells Fargo | Lowers | Overweight | $157.00 | $163.00 |
| Yatin Suneja | Guggenheim | Raises | Buy | $205.00 | $200.00 |
| Ami Fadia | Needham | Maintains | Buy | $154.00 | $154.00 |
Key Insights:
- Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Axsome Therapeutics. This offers insight into analysts' perspectives on the current state of the company.
- Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Axsome Therapeutics compared to the broader market.
- Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Axsome Therapeutics's stock. This comparison reveals trends in analysts' expectations over time.
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Axsome Therapeutics's market standing. Stay informed and make well-considered decisions with our Ratings Table.
Stay up to date on Axsome Therapeutics analyst ratings.
All You Need to Know About Axsome Therapeutics
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
Axsome Therapeutics: Financial Performance Dissected
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3M period, Axsome Therapeutics showcased positive performance, achieving a revenue growth rate of 63.22% as of 30 September, 2025. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Axsome Therapeutics's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -27.62%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Axsome Therapeutics's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -64.34%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -7.22%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 2.96, caution is advised due to increased financial risk.
Understanding the Relevance of Analyst Ratings
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
